Last reviewed · How we verify
Pemetrexed, Carboplatin, Pembrolizumab
Pemetrexed, Carboplatin, Pembrolizumab is a Small molecule drug developed by Samsung Medical Center. It is currently in Phase 2 development. Also known as: Alimta, Preizer carboplatin, keytruda.
At a glance
| Generic name | Pemetrexed, Carboplatin, Pembrolizumab |
|---|---|
| Also known as | Alimta, Preizer carboplatin, keytruda |
| Sponsor | Samsung Medical Center |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18) (PHASE1)
- A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors (PHASE1)
- A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC (PHASE3)
- A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) (PHASE3)
- Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial (PHASE3)
- Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) (PHASE3)
- Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) (NA)
- Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pemetrexed, Carboplatin, Pembrolizumab CI brief — competitive landscape report
- Pemetrexed, Carboplatin, Pembrolizumab updates RSS · CI watch RSS
- Samsung Medical Center portfolio CI
Frequently asked questions about Pemetrexed, Carboplatin, Pembrolizumab
What is Pemetrexed, Carboplatin, Pembrolizumab?
Pemetrexed, Carboplatin, Pembrolizumab is a Small molecule drug developed by Samsung Medical Center.
Who makes Pemetrexed, Carboplatin, Pembrolizumab?
Pemetrexed, Carboplatin, Pembrolizumab is developed by Samsung Medical Center (see full Samsung Medical Center pipeline at /company/samsung-medical-center).
Is Pemetrexed, Carboplatin, Pembrolizumab also known as anything else?
Pemetrexed, Carboplatin, Pembrolizumab is also known as Alimta, Preizer carboplatin, keytruda.
What development phase is Pemetrexed, Carboplatin, Pembrolizumab in?
Pemetrexed, Carboplatin, Pembrolizumab is in Phase 2.
Related
- Manufacturer: Samsung Medical Center — full pipeline
- Also known as: Alimta, Preizer carboplatin, keytruda
- Compare: Pemetrexed, Carboplatin, Pembrolizumab vs similar drugs
- Pricing: Pemetrexed, Carboplatin, Pembrolizumab cost, discount & access